Nasal Immunotherapy Shows Promise in Reducing Inflammation and Boosting Cognitive Function in Alzheimer's Disease

▴ Alzheimer's Disease
The discovery of nasal immunotherapy with anti-CD3 as a potential treatment for Alzheimer's disease represents a ray of hope for the millions of individuals and their families affected by this devastating condition.

Alzheimer's disease is a devastating condition characterized by neurodegeneration and inflammation in the brain. Finding effective treatments for this complex disease has been challenging, as most existing therapies focus on targeting amyloid beta plaques and require early intervention through intravenous therapy. However, recent research has unveiled a promising new approach - nasal immunotherapy with anti-CD3 - which has shown potential in reducing inflammation and enhancing cognitive function in Alzheimer's disease.

The Breakthrough:

In a groundbreaking study published in the journal PNAS, researchers have uncovered preclinical evidence suggesting that nasal immunotherapy can offer significant benefits to individuals battling Alzheimer's disease. What sets this therapy apart is its ability to reduce inflammation and improve cognition independently of amyloid beta plaque levels.

Anti-CD3 Nasal Immunotherapy:

The novel nasal immunotherapy, referred to as anti-CD3, has shown remarkable results in Alzheimer's mouse models. The treatment involves administering anti-CD3 intranasally three times a week for five months. During this time, researchers observed a notable decrease in the activation of microglia, which are immune cells responsible for inflammation in the brain.

Improved Cognitive Function:

The positive effects of anti-CD3 immunotherapy were not limited to reduced inflammation. Treated mice exhibited enhanced cognitive function as demonstrated by improved performance in various behavioral tests, including a water maze. These improvements in cognition are a significant breakthrough, as cognitive decline is a hallmark of Alzheimer's disease.

Immune System Response:

The study also unveiled intriguing changes in gene expression patterns within the brain and an expansion of regulatory T cells, which play a crucial role in fighting diseases in the body. Importantly, all of these changes occurred independently of amyloid beta plaque levels, suggesting that this therapy targets aspects of Alzheimer's disease that have previously been challenging to address.

Promising Implications:

Corresponding author Howard L. Weiner from the Department of Neurology at Brigham and Women's Hospital in the US expressed "We provide evidence that intranasal anti-CD3 therapy can dampen microglia activation and expand T cells in a murine model of Alzheimer’s. This represents a unique approach to treating later-stage Alzheimer’s that can be applied to other inflammatory disease conditions as well."

Future Prospects:

Researchers are now planning to further investigate the potential of anti-CD3 immunotherapy in combination with anti-amyloid therapies in animal studies. This step is crucial in understanding how these treatments can work together to provide a comprehensive approach to Alzheimer's disease treatment. Ultimately, the goal is to advance this promising therapy into human clinical trials.

Building on Success:

This exciting breakthrough builds upon previous research by the same team, who explored the use of foralumab, the only fully human anti-CD3 monoclonal antibody treatment, in patients with COVID-19 and multiple sclerosis (MS). These efforts underscore the versatility of anti-CD3 immunotherapy in addressing a range of inflammatory conditions.


The discovery of nasal immunotherapy with anti-CD3 as a potential treatment for Alzheimer's disease represents a ray of hope for the millions of individuals and their families affected by this devastating condition. As researchers continue to explore this innovative approach, there is optimism that it may offer a unique and effective way to combat Alzheimer's disease, while also holding promise for other inflammatory diseases. Further studies and clinical trials will shed more light on the full potential of this therapy in the fight against Alzheimer's

Tags : #alzheimer #nasal #immunotherapy #brainhealth #inflammatorydiseases #anti-CD3 #COVID19 #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Top 4 IVF Centres for High Success RatesJune 24, 2025
Former President Ram Nath Kovind to Inaugurate National Conference of CA Students 2025 in KolkataJune 24, 2025
Bollywood actor Salman Khan says he is suffering from a brain aneurysm, what you need to know about the conditionJune 24, 2025
Butterfly Unveils a Bold New Identity That Celebrates Change and Champions the Original YouJune 24, 2025
8 Daily Habits to Keep Arthritis at BayJune 24, 2025
Food Safety and Drug Administration (FDA), Goa, National Association of Street Vendors of India (NASVI) and Nestlé India expand Project ‘Serve Safe Food’ in GoaJune 24, 2025
Top 4 Startups Driving Credit Risk Innovation in India’s Healthcare and Pharma SectorJune 24, 2025
Sova Health to Host a Free Masterclass on World Microbiome Day, Demystifying Digestive HealthJune 24, 2025
Doctor-Approved Hacks for Better Sleep TonightJune 24, 2025
Indian Assistive Technology Pioneer Prateek Madhav Champions Global Disability Tech Reform with The Royal Society of London Report LaunchJune 24, 2025
Wow! Momo Launches India’s First Gluten-Free Range of Momos – A Game-Changer for Health Conscious FoodiesJune 24, 2025
Medicolegal Risks in TelemedicineJune 24, 2025
Digital Mental Health Clinics in Tier-2 CitiesJune 24, 2025
AssisTech Foundation Hosts Inclusive Job Festival for Persons with DisabilitiesJune 23, 2025
Travel with Ease: Why Congestion Patches Are the Smart Traveler’s Secret WeaponJune 23, 2025
Paper-Tech Platform Paper Arizona Hits ₹100 Cr Annual Revenue Milestone, Eyes IPO Listing in 2026June 23, 2025
Eat Better to enhance its Quick Commerce Operations with UnicommerceJune 23, 2025
Stahl Unveils Blacksmith Signature Cast Iron Tawas: A Classic Essential with a Modern Update for Timeless Indian KitchensJune 23, 2025
Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trialsJune 23, 2025
Finding strength in struggle for gender equality and human rightsJune 23, 2025